By |

Profile

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).

Contact Information

Website: www.amgen.com
Email: investor.relations@amgen.com
Main Phone: +1 805 447-1000
Address: One Amgen Center Drive
Address 2: Suite 2650
State: CA
City / Town: Thousand Oaks
Country: USA
Postal Code: 91320-1799

Issuer Information

Exchange: NGS
CEO: Robert A. Bradway
Employees: 21500
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More

Profile

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).

Contact Information

Website: www.amgen.com
Email: investor.relations@amgen.com
Main Phone: +1 805 447-1000
Address: One Amgen Center Drive
Address 2: Suite 2650
State: CA
City / Town: Thousand Oaks
Country: USA
Postal Code: 91320-1799

Issuer Information

Exchange: NGS
CEO: Robert A. Bradway
Employees: 21500
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More
$ 236.66 $ -0.94 (-0.40%)
Last Price 236.66 Change $ -0.94 Change % -0.40 Tick N/A
Bid 236.65 Bid Size 300.00 Ask 236.68 Ask Size 200.00
Open 238.75 High 239.70 Low 235.76 Prev Close 237.60
Last Trade Volume 998,956 52 Wk Hi 245.00 52 Wk Low 166.31
Market Cap 140.6 bi Ex-Div Date Div Rate 6.40 Yield 2.6940
Shares 594,183,541.00 EPS (TTM) 13.03 PE Ratio 18.50 Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 45 74
Number of Buys 23 31
Number of Sells 22 43
Net Activity -8304 75103
Last 10 Buys Shares
Fred Hassan 1,000
Fred Hassan 1,000
Frank C. Herringer 1,000
Frank C. Herringer 1,000
Robert A. Bradway 1,000
Last 10 Sell Shares
Sean Harper 1,000
Sean Harper 1,000
Sean Harper 1,000
Sean Harper 1,000
Sean Harper 1,000
Sean Harper 1,000
Sean Harper 1,000
Sean Harper 1,000
De Francois Carbonnel 1,000
Sean Harper 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 224 224 224 224
Low Target Price Estimate 165 165 165 165
Mean Target Price Estimate 193.94 193.94 193.12 193.94
Standard Deviation 15.01 15.01 14.92 15.01
Date of Most Recent Estimate 06/03/18 05/22/18 05/22/18 06/03/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 7 7 7 7
Moderate Buy 1 1 1 1
Hold 12 13 14 14
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.22 2.26 2.3 2.3